CEP70 and neoplasm: In conclusion, our findings demonstrated that the engineered T cells expressing CD3εζ28 and/or BiTE could be highly activated and revealed strong antitumor activity in xenograft tumor models, which provides preclinical evidence for the therapeutic potential of CD3εζ28 fusion protein.